Important Risk Minimisation Information for Healthcare Professionals.

This video shows the complete steps required for the correct preparation and administration of Eligard® (leuprorelin acetate). The video can be watched in full or viewed as individual chapters. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks. It is recommended that healthcare professionals who prepare/administer Eligard® review these instructions on a regular basis to ensure they always follow the correct steps.

Play Video
Play All
1
Preparing the syringes
2
Reconstruction of the product
3
Administering the product
4
Disposal of the syringes

Please refer to www.medicines.ie or to the HPRA website: www.hpra.ie to access the current version of the SmPC.

All cases of incorrect storage, preparation, reconstitution and administration of Eligard® or any other adverse reaction should be reported to Recordati Ireland Ltd. Tel.: 021 437 9400. email: medinfo@recordati.co.uk or to HPRA Pharmacovigilance, Website: www.hpra.ie

Back

RIL-ELI-23-001

DOP: July 2023

Adverse event reporting
Poster
Disclaimer
Terms of use

All cases of incorrect storage, preparation, reconstitution, and administration of Eligard® or any other adverse reactions should be reported to Recordati Ireland Ltd. Tel.: 021 437 9400. email: medinfo@recordati.co.uk , or to HPRA Pharmacovigilance, Website: www.hpra.ie

INSTRUCTIONS FOR PREPARATION, MIXING AND ADMINISTRATION Icona PDF

Information contained seeks to reinforce the safe and effective conditions of use of Eligard® according to the approved Summary of Product Characteristics.

The tool does not generate data or read-out that can be considered as of clinical predictive value or inform dosing adjustments or therapeutic monitoring.

Information provided in this tool is a reminder on how to use Eligard® safely and effectively. The HCPs should refer to the approved SmPC for guidance.

Malfunction of the software would unlikely impact on patient care because the dosing is individually determined following the prescribing physician’s clinical assessment of the patient under his care. Nor does it seek to replace the health professional’s skills to prepare and administer the treatment according to the approved Summary of Product Characteristics.

Terms and Conditions Icona PDF
Ok
Back
Terms of use

Lek Eligard je zamenjen sa lekom Eligard sa sistemom spojenih špriceva.

Molimo izaberite lek koji VI imate, birajući jednu od donjih opcija.

Eligard

Izaberite

Eligard sa sistemom spojenih špriceva

Izaberite

ELI_2019_0003_AB

Datum pripreme: Decembar 2024.

Terms of use

This tool is intended for healthcare professionals responsible for administering Eligard®.

For further information, ask your doctor

Back
Disclaimer
Adverse event reporting
Poster
Terms of use

Important Risk Minimisation Information for Healthcare Professionals.

This video shows the complete steps required for the correct preparation and administration of Eligard® (leuprorelin acetate). The video can be watched in full or viewed as individual chapters. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks. It is recommended that healthcare professionals who prepare/administer Eligard® review these instructions on a regular basis to ensure they always follow the correct steps.

Are you a healthcare professional?

Yes
No

This tool has been funded and developed by Recordati S.p.A.

Back

RIL-ELI-23-001

DOP: July 2023

Terms of use